219 related articles for article (PubMed ID: 19934279)
1. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH
Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279
[TBL] [Abstract][Full Text] [Related]
2. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
4. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
[TBL] [Abstract][Full Text] [Related]
5. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Zhang YW; Staal B; Essenburg C; Su Y; Kang L; West R; Kaufman D; Dekoning T; Eagleson B; Buchanan SG; Vande Woude GF
Cancer Res; 2010 Sep; 70(17):6880-90. PubMed ID: 20643778
[TBL] [Abstract][Full Text] [Related]
6. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
7. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.
Zou HY; Li Q; Lee JH; Arango ME; Burgess K; Qiu M; Engstrom LD; Yamazaki S; Parker M; Timofeevski S; Cui JJ; McTigue M; Los G; Bender SL; Smeal T; Christensen JG
Mol Cancer Ther; 2012 Apr; 11(4):1036-47. PubMed ID: 22389468
[TBL] [Abstract][Full Text] [Related]
9. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
10. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
[TBL] [Abstract][Full Text] [Related]
11. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
[TBL] [Abstract][Full Text] [Related]
12. MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
Ortiz-Zapater E; Lee RW; Owen W; Weitsman G; Fruhwirth G; Dunn RG; Neat MJ; McCaughan F; Parker P; Ng T; Santis G
PLoS One; 2017; 12(1):e0170798. PubMed ID: 28141869
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
[TBL] [Abstract][Full Text] [Related]
14. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities.
Wang Y; Zhan Z; Jiang X; Peng X; Shen Y; Chen F; Ji Y; Liu W; Shi Y; Duan W; Ding J; Ai J; Geng M
Oncotarget; 2016 Jun; 7(25):38091-38104. PubMed ID: 27191264
[TBL] [Abstract][Full Text] [Related]
15. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.
Egile C; Kenigsberg M; Delaisi C; Bégassat F; Do-Vale V; Mestadier J; Bonche F; Bénard T; Nicolas JP; Valence S; Lefranc C; Francesconi E; Castell C; Lefebvre AM; Nemecek C; Calvet L; Goulaouic H
Mol Cancer Ther; 2015 Feb; 14(2):384-94. PubMed ID: 25504634
[TBL] [Abstract][Full Text] [Related]
16. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
[TBL] [Abstract][Full Text] [Related]
17. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.
Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F; Zimmer Y
Mol Cancer Ther; 2013 Nov; 12(11):2415-24. PubMed ID: 24061647
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
19. Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration.
Kim JW; Lee MN; Jeong BC; Oh SH; Kook MS; Koh JT
Eur J Pharmacol; 2017 Jul; 806():10-17. PubMed ID: 28322831
[TBL] [Abstract][Full Text] [Related]
20. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.
He CX; Ai J; Xing WQ; Chen Y; Zhang HT; Huang M; Hu YH; Ding J; Geng MY
Acta Pharmacol Sin; 2014 Jan; 35(1):89-97. PubMed ID: 24241352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
